Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HXN-1002
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,845.0 million
Deal Type : Licensing Agreement
Earendil Labs Licenses Bispecific Antibodies for Autoimmune use from Sanofi
Details : Under the licensing agreement, Sanofi will obtain exclusive worldwide rights to antibody, HXN-1002. It is designed to provide a treatment option for patients with ulcerative colitis.
Product Name : HXN-1002
Product Type : Antibody
Upfront Cash : $125.0 million
April 17, 2025
Lead Product(s) : HXN-1002
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,845.0 million
Deal Type : Licensing Agreement